CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 120 enrolled
Drug / intervention
Empagliflozin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05359432
NCT05359432Phase 4Completed
CompareCT.gov

Comparison of Empaglifozin and Vildagliptin in Efficacy and Safety in Type 2 Diabetes Mellitus

Getz Pharma·interventional·Posted May 3, 2022·Updated May 3, 2022

In Brief

A Phase 4 clinical trial evaluating Empagliflozin and Vildagliptin for Type 2 Diabetes. Completed, enrolled 120 participants across 1 site.

Detailed Summary

The aim of this study is to perform a comparison of the efficacy and safety of empagliflozin and vildagliptin in patients with Type 2 Diabetes Mellitus open labelled, multi-centric, parallel, randomized control trial In Type 2 Diabetes patients, impact of empagliflozin (10 mg once or twice daily) versus vildagliptin (50 mg once or twice daily) assessed for Efficacy \& safety parameters to be measured at both the baseline and 24-week visits.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesPakistan
Collaborators--

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedMay 3, 2022
Enrollment StartJul 1, 2020
Primary CompletionAug 10, 2021
Study CompletionAug 18, 2021
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 4.2 years ago

Interventions

Empagliflozindrug

Receiving allocated drug dosage as per clinical needs

Vildagliptindrug

Receiving allocated drug dosage as per clinical needs